EVOLUS INC
EOLSNASDAQTrading Snapshot
- Day Range
- $8.04 – $8.25
- 52-Week Range
- $3.86 – $8.43
- Volume
- $2.57B
- Avg Volume
- $3.36B
- Shares Outstanding
- 65.9M
- Next Earnings
- Oct 3, 2026
Fundamentals Snapshot
- Annual Revenue
- $297M
- Last Q Revenue
- $84M
- P/E Ratio
- -15.7
- P/S Ratio
- 1.7x
- EPS (TTM)
- $-0.52
- Dividend Yield
- 0.00%
Why Investors Own EOLS
- ✓High-growth profile — revenue up +33.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 72% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About EVOLUS INC
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Evolus: The Injectable Platform Is Becoming The Real Moat
Evolus is evolving into a multi-product aesthetics platform, leveraging its distribution network and loyalty ecosystem to drive operating leverage and...
Evolus, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-06. The following slide deck was published by Evolus, Inc.
Evolus (NASDAQ:EOLS) Tops Q2 EPS Estimates and Raises Revenue Guidance, Shares Gain 5.7%
Evolus Q2 revenue meets estimates, EPS beats; shares rise 5.7% on third straight positive EBITDA and raised 2026 guidance.
Evolus, Inc. (EOLS) Q2 2026 Earnings Call Transcript
Evolus, Inc. (EOLS) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDTCompany ParticipantsNareg Sagherian - Head of Global Investor Relations & Corporate...
Evolus Q2 EPS $(0.12), Sales $84.084M Beat $81.603M Estimate
Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.13) by 0 percent. This is a 47.83 percent increase over losses of $(0.23) per share from the same
Evolus Raises FY2026 Sales Guidance from $327.000M-$337.000M to $330.000M-$337.000M vs $330.445M Est
Evolus (NASDAQ:EOLS) raises FY2026 sales outlook from $327.000 million-$337.000 million to $330.000 million-$337.000 million vs $330.445 million estimate.